The American Academy of Otolaryngology-Head and Neck Surgery considers bone conduction hearing devices, including implantation of a percutaneous or transcutaneous device and use of a bone conduction oral appliance or bone conduction scalp device to be acceptable, and in many cases preferred, procedures in the the treatment of conductive or mixed hearing loss and single-sided deafness when performed by-a qualified otolaryngologist-head and neck surgeon. Use of these devices, which have been Food and Drug Administration (FDA)-approved for these indications, should adhere to the restrictions and guidelines specified by the appropriate governing agency, such as the FDA in the United States and other similar regulatory agencies in countries other than the United States.
- Crowson MG, Tucci DL. Mini review of the cost-effectiveness of unilateral osseointegrated implants in adults: Possibly cost-effective for the correct indication. Audiol Neurotol 2016;21(2):69-71.
- Baker S, Centric A, Chenupati SK. Innovation in abutment-free bone-anchored hearing devices in children: Updated results and experience. Int J Pediatr Otorhinolaryngol 2015;79(10):1667-72.
- Saroul N, Akkari M, Pavier Y, et al. Long-term benefit and sound localization in patients with singlesided deafness rehabilitated with an osseointegrated bone-conduction device. Otol Neurotol 2013;34(1):111-4.
- Monksfield P, Jowett S, Reid A, et al. Cost-effectiveness analysis of the bone-anchored hearing device. Otol Neurotol 2011:32:1192-97.
- Lin LM, Bowditch S, Anderson MJ, et al. Amplification in the rehabilitation of unilateral deafness: speech in noise and directional hearing effects with bone-anchored hearing and contralateral routing of signal amplification. Otol Neurotol 2006; 27(2):172-82.